![]() Baird assumed coverage on bluebird bio in a report on Monday, March 6th. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $7.00.Ī number of research analysts have recently commented on BLUE shares. Three investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and two have given a buy recommendation to the company. ![]() ![]() ( NASDAQ:BLUE – Get Rating) have been given a consensus recommendation of “Hold” by the ten brokerages that are presently covering the firm, reports.
0 Comments
Leave a Reply. |